The winners were announced on March 25, 2026, during DCAT Week in New York. The award is based on an independent study by the Tufts Center for the Study of Drug Development, which incorporates quantitative performance metrics as well as verified customer feedback from pharmaceutical and biotech decision makers.
We strive to provide long-term support that is aligned with our customers’ needs. This award confirms our commitment to the highest standards of quality, reliability, and collaborative partnership. Above all, it recognizes the efforts of our more than 7,300 employees around the world.
Lars Hahn, Senior Vice President Global Sales Organization
As a strategic partner, Vetter supports its customers across the entire value chain, including process development, clinical and commercial filling, and assembly and packaging solutions for injectable medications.
In response to the growing demand for complex biological medicines, the company is making targeted investments to expand its global infrastructure. It plans to invest approximately €2 billion in Europe and the United States by 2035.
